Drug Profile


Alternative Names: RS 66271

Latest Information Update: 09 Jun 2009

Price : $50

At a glance

  • Originator Roche Bioscience - UCB (JV)
  • Class Peptides
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 09 Jun 2009 Semparatide licensed to Tokai Pharmaceuticals worldwide
  • 29 Dec 1999 A study of women with postmenopausal osteoporosis has been added to the Women's health and Musculoskeletal disorders therapeutic trials sections
  • 19 Feb 1999 RS 66271 is now called semparatide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top